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Introduction {#sec1-1}
============

Stroke is a common, frequently occurring disease that seriously harms human health. The results from an epidemiological survey on cerebrovascular diseases in China showed that the age-corrected prevalence, annual incidence and mortality rates of stroke were 1114.8/100,000, 246.8/100,000, and 114.8/100,000, respectively (Wang et al., 2017). Ischemic stroke is the most common type of stroke, accounting for 69.6--77.8% of all stroke cases (Wang et al., 2017). Brain-derived neurotrophic factor (BDNF) is one of the members of the neurotrophic factor family. Mature BDNF is an alkaline protein with 119 amino acid residues and a relative molecular weight of 14 kDa (Mowla et al., 2001). It is mainly synthesized and secreted by neurons and glial cells in the central nervous system (Mowla et al., 2001; Wurzelmann et al., 2017). There are two secretory modes of BDNF: constitutive release and activity-dependent release (Poo, 2001). In recent years, studies have suggested that BDNF plays important roles in neuroprotection, neuroplasticity and neuroregeneration (Lee et al., 2003; Machaliński et al., 2012; Zhao et al., 2017).

The secretion and functions of BDNF depend on the expression of the *BDNF* gene. Single-nucleotide polymorphisms are one of the most common types of human genetic variation. Single-nucleotide polymorphisms in the *BDNF* gene may affect BDNF secretion and/or function, thereby affecting the incidence, severity and prognosis of ischemic stroke (Egan et al., 2003; Orefice et al., 2013; Kotlęga et al., 2017). A large number of single-nucleotide polymorphisms in the *BDNF* gene are known. It has been reported that the mutation at the rs7124442 (C/T) locus in the 3′-untranslated region (3′UTR) of the *BDNF* gene is associated with the recovery of cognitive functions after traumatic brain injury (Rostami et al., 2011), but few studies on this topic have been published. No studies have reported on the correlation between nucleotide variations at this locus and susceptibility to ischemic stroke, neurological deficits during the acute phase of ischemic stroke and ischemic stroke prognosis. Additionally, rs6265 (A/G) is one of the most studied and most clinically significant single-nucleotide polymorphism loci of the *BDNF* gene (Kotlęga et al., 2017). Rs6265 is a missense mutation located in the exon of the *BDNF* gene and is present in approximately 30--50% of the population (Shimizu et al., 2004). This mutation of G to A changes the amino acid at position 66 of the BDNF precursor protein (pro-BDNF) from valine to methionine (Val66Met). Although this missense mutation does not affect the function and basic secretion of *BDNF*, it causes a 25% reduction in the activity-dependent secretion of BDNF (Egan et al., 2003). However, the results from existing clinical studies on the correlations of polymorphism at the rs6265 locus with ischemic stroke susceptibility and prognosis are not entirely consistent (Cramer et al., 2012; Kim et al., 2012, 2013; Zhao et al., 2013; Stanne et al., 2014; Keshavarz et al., 2016). Animal studies have found a decrease in *BDNF* levels in the central nervous systems of knock-in mice with a *BDNF* (Met/Met) mutation; this reduction was associated with the severity of motor defects (Qin et al., 2011). However, the rs6265 polymorphism has not been found to be associated with the severity of neurological deficits during the acute phase of ischemic stroke in clinical studies (Zhao et al., 2013; Stanne et al., 2014).

This study investigated the correlations of *BDNF* polymorphism at the rs7124442 locus with the occurrence, severity and prognosis during the acute phase in ischemic stroke patients in the Han population of southwest China. The rs6265 locus was also examined for the presence of the these correlations in ischemic stroke patients.

Participants and Methods {#sec1-2}
========================

Participants {#sec2-1}
------------

This was a case-control study. Ischemic stroke patients treated and registered at the Department of Neurology in West China Hospital, Sichuan University, China, from September 2011 to December 2014 were recruited. The *2010 China Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke* was used as the reference for the diagnostic criteria adopted in this study (Acute Ischemic Stroke Diagnosis and Treatment Writing Group of Cerebrovascular Disease in Neurology Branch of Chinese Medical Association, 2010). Assessments were made by more than two neurologists. These neurologists took part in the study, and were blind to the participants' genotypes. The specific inclusion criteria were as follows: patients aged ≥18 years in the Han ethnic population of southwest China; patients who met the ischemic stroke diagnostic criteria and were admitted to hospital within 7 days of disease onset; patients who had ischemic stroke lesions confirmed by computed tomography or magnetic resonance imaging; and patients who had new-onset acute ischemic stroke or who had a history of stroke but with no residual dysfunction (score ≤ 1 point on a modified Rankin scale) (Cheng et al., 2014). The exclusion criteria were as follows: subjects with transient cerebral ischemia or hemorrhagic stroke (but not excluding hemorrhagic transformation after ischemic stroke); and subjects with complications of primary subarachnoid hemorrhage, subdural hematoma, cerebrovascular malformations, intracranial venous thrombosis or intracranial tumors. The subjects in the control group were recruited from the Department of Neurology of West China Hospital over the same period. They showed no history of stroke during clinical examination and cerebral infarction lesions in cranial imaging (computed tomography or magnetic resonance imaging). The exclusion criteria of the control group were the same as those of the ischemic stroke group.

Written informed consent was obtained from all participants or their next-of-kin, when participants were unable to communicate or write. The study protocol was approved by the Ethics Committee of West China Hospital, Sichuan University, China (approval ID number 2008\[4\]) on July 25, 2008 (**Additional file 1**) and conducted in accordance with the ethical guidelines of the 1975 *Declaration of Helsinki*. The study flow chart is shown in **[Figure 1](#F1){ref-type="fig"}**. This study follows the Standard Protocol Items: STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidance for study (**[Additional file 2](#T7){ref-type="table"}**).

![Study flow chart.](NRR-14-1404-g002){#F1}

Collection of clinical information {#sec2-2}
----------------------------------

General clinical information, such as age and sex, along with the assessment of risk factors, including history of hypertension, diabetes, hyperlipidemia, atrial fibrillation, smoking and drinking, were collected by neurologists. Ischemic stroke was divided into the following five types according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification: large-artery atherosclerosis, cardioembolism, small-artery occlusion, stroke of other determined etiologies and stroke of undetermined etiology (Adams et al., 1993). Meanwhile, the severity of their neurological deficits in the acute phase immediately after admission to the hospital was assessed using the National Institutes of Health Stroke Scale (NIHSS) (Lyden, 2017). A stroke with an NIHSS score ≤ 6 was considered mild, while a stroke with an NIHSS score ≥ 7 was considered severe. Early prognosis was evaluated using Modified Rankin Scale (mRS) scores (Cheng et al., 2014) from ischemic stroke patients when they were discharged. Patients with mRS scores ≤ 1 were considered as having good prognoses, while those with mRS scores ≥ 2 were considered as having poor prognoses. The above criteria were employed to remain consistent with the criteria adopted in existing relevant studies on the correlation between *BDNF* single-nucleotide polymorphisms and ischemic stroke to facilitate the comparison of findings from different populations (Zhao et al., 2013; Stanne et al., 2014).

Blood sample collection {#sec2-3}
-----------------------

Fasting peripheral venous blood samples (5 mL) were collected from superficial veins of the upper extremity at the elbow of each participant in the morning, with ethylenediamine tetraacetic acid as the anticoagulant. The samples were then stored at −20°C for extraction of genomic DNA from whole blood.

Genotyping {#sec2-4}
----------

Genomic DNA was extracted from peripheral blood using an AxyPrep Blood Genomic DNA Maxiprep Kit (Axygen, Union City, CA, USA). Genotyping of rs7124442 and rs6265 was performed using Kompetitive Allele Specific polymerase chain reaction genotyping technology (LGC Genomics, formerly KBioscience, <http://www.lgcgenomics.com/>).

Statistical analysis {#sec2-5}
--------------------

To compare differences in the clinical backgrounds of the participants, SPSS for Windows (Version 21.0, IBM, Armonk, NY, USA) was employed for chi-square or independent samples *t*-test analyses. The Hardy-Weinberg equilibrium test was performed using the SHEsis software (Shi and He, 2015). Three common genetic analysis methods (allele frequency, dominance model and recessive model) were used to analyze the correlations between polymorphism of the selected locus and the risk, severity of neurological deficits and early prognosis of ischemic stroke. If "A" represents wild type and "a" represents mutant type, the methods of allele mean participants with the a alleles *versus* those with the A allele, while the dominance model means aa + Aa *versus* AA; the recessive model means aa *versus* Aa + AA. Chi-square testing was employed to analyze the distribution of allele frequencies between the ischemic stroke and control groups. Logistic regression analysis was used in the dominant and recessive models to correct for the relevant risk factors (sex, age, smoking history, history of alcohol consumption, hypertension, diabetes, hyperlipidemia and atrial fibrillation). The three types of analyses described above were performed using PLINK v1.07 (<http://pngu.mgh.harvard.edu/purcell/plink/>) (Purcell et al., 2007). Values of *P* \< 0.05 were considered statistically significant.

Results {#sec1-3}
=======

Baseline characteristics of ischemic stroke cases and controls {#sec2-6}
--------------------------------------------------------------

A total of 778 ischemic stroke patients and 865 control participants were included in this study. The comparison of general clinical information between the two groups is shown in **[Table 1](#T1){ref-type="table"}**. The differences in age and sex were statistically significant between the two groups (*P* \< 0.001). Among the common risk factors for ischemic stroke, the proportions of participants with hypertension, diabetes, hyperlipidemia, atrial fibrillation and history of smoking were significantly higher in the ischemic stroke group than those in the control group (*P* \< 0.001). No significant differences were found in alcohol consumption between the ischemic stroke and control groups (*P* = 0.132).

###### 

Baseline characteristics of ischemic stroke cases and controls

  Characteristic        Control (*n* = 865)   Ischemic stroke                                                                                    
  --------------------- --------------------- ----------------- -------------- ----------- -------------- ----------- -------------- ----------- --------------
  Age (year)            51.7±14.7             64.0±12.6         \< 0.001^\*^   65.1±11.9   \< 0.001^\*^   65.2±13.4   \< 0.001^\*^   62.4±11.8   0.002^\*^
  Sex (male)            438(50.6)             475(61.1)         \< 0.001^\*^   191(68.0)   \< 0.001^\*^   76(47.5)    0.466          135(64.3)   \< 0.001^\*^
  Hypertension          165(19.1)             519(66.7)         \< 0.001^\*^   196(69.8)   \< 0.001^\*^   81(50.6)    \< 0.001^\*^   167(79.5)   \< 0.001^\*^
  Diabetes              58(6.7)               248(31.9)         \< 0.001^\*^   93(33.1)    \< 0.001^\*^   39(24.4)    \< 0.001^\*^   81(38.6)    \< 0.001^\*^
  Hyperlipidemia        89(10.3)              132(17.0)         \< 0.001^\*^   46(16.4)    0.06           14(8.8)     0.552          55(26.2)    \< 0.001^\*^
  Atrial fibrillation   5(0.5)                141(18.1)         \< 0.001^\*^   2(0.7)      0.803          127(79.4)   \< 0.001^\*^   2(1.0)      0.545
  Smoking               221(25.5)             268(34.4)         \< 0.001^\*^   122(43.4)   \< 0.001^\*^   33(20.6)    0.185          77(36.7)    0.001^\*^
  Drinking              160(18.5)             167(21.5)         0.132          69(24.6)    0.027^\*^      28(17.5)    0.765          47(22.4)    0.200

LAA: Large-artery atherosclerosis; SAO: small-artery occlusion. Data are expressed as *n* (percent) with the exception of age. The data for age are expressed as the mean ± SD. \**P* \< 0.05, *vs*. control group (chi-square or independent samples*t*-test).

The results from the TOAST classification are shown in **[Table 1](#T1){ref-type="table"}**. The ischemic stroke group included 281 cases with large-artery atherosclerosis. Statistically significant differences were found in age and sex between the large-artery atherosclerosis group and the control group (*P* \< 0.001). Rates of hypertension, diabetes and history of smoking or drinking were higher in the large-artery atherosclerosis group than in the control group (all *P* \< 0.05). There were 160 cases of cardioembolism in the ischemic stroke group, with a significant difference in age when compared with the control group (*P* \< 0.001). The rates of hypertension, diabetes and atrial fibrillation were all higher in the cardioembolism group than those of the control group (*P* \< 0.001). A total of 210 cases of small-artery occlusion were included in the ischemic stroke group. Significant differences in age (*P* = 0.002) and sex (*P* \< 0.001) were detectable between the ischemic stroke group and the control group (*P* \< 0.01). The rates of hypertension, diabetes, hyperlipidemia and history of smoking were significantly higher in the small-artery occlusion group than in the control group (all *P* \< 0.05).

As shown in the analysis of the subtypes of the ischemic stroke group in **[Table 2](#T2){ref-type="table"}**, 477 mild stroke patients (61.3%) (NIHSS score ≤ 6) and 301 (38.7%) severe stroke patients (NIHSS score ≥ 7) were included. No significant differences were observed in sex, age, or rates of hypertension, diabetes, hyperlipidemia or history of drinking or smoking between the two groups (*P* \> 0.05). However, the rate of atrial fibrillation was lower in the mild stroke group than that of the severe stroke group (*P* \< 0.001). There were 189 patients (24.3%) with good prognosis (mRS score ≤ 1; good prognosis group) and 589 patients (75.7%) with poor prognosis (mRS score ≥ 2; poor prognosis group). These two groups exhibited no significant differences in sex, age, rate of diabetes or hyperlipidemia or history of drinking or smoking (*P* \> 0.05). However, the rate of atrial fibrillation in the good prognosis group was lower than that in the poor prognosis group (*P* = 0.045). The rate of hypertension was higher in the good prognosis group than in the poor prognosis group (*P* = 0.022).

###### 

Baseline characteristics of ischemic stroke subtypes

  Characteristic        Stroke severity at admission   Acute functional outcome                                          
  --------------------- ------------------------------ -------------------------- -------------- ----------- ----------- -----------
  Age (year)            63.8±12.3                      64.3±12.9                  0.569          64.5±12.4   63.9±12.6   0.566
  Sex (male)            297(62.3)                      178(59.1)                  0.384          118(62.4)   357(60.6)   0.655
  Hypertension          321(67.3)                      198(65.8)                  0.662          139(73.5)   380(64.5)   0.022^\*^
  Diabetes              163(34.2)                      85(28.2)                   0.084          59(31.2)    189(32.1)   0.823
  Hyperlipidemia        89(18.7)                       43(14.3)                   0.114          35(18.5)    97(16.5)    0.514
  Atrial fibrillation   67(14.0)                       74(24.6)                   \< 0.001^\*^   25(13.2)    116(19.7)   0.045^\*^
  Smoking               163(34.2)                      105(34.9)                  0.839          58(30.7)    210(35.7)   0.211
  Drinking              105(22.0)                      62(20.6)                   0.64           37(19.6)    130(22.1)   0.467

Data are expressed as *n* (percent), except age. The data for age are expressed as the mean ± SD. \**P* \< 0.05 (chi-square or independent samples *t*-test). NIHSS: National Institutes of Health Stroke Scale; mRS: Modified Rankin Scale.

Genotype and allele frequency distributions of single-nucleotide polymorphisms in ischemic stroke cases and controls {#sec2-7}
--------------------------------------------------------------------------------------------------------------------

As shown in **Tables [3](#T3){ref-type="table"}** and **[4](#T4){ref-type="table"}**, in the comparative analysis between the control group and the subtype groups based on TOAST classification in ischemic stroke patients, we performed logistic regression analysis for the rs7124442 locus to correct for potential confounding factors (sex, age, smoking, drinking, hypertension, diabetes, hyperlipidemia and atrial fibrillation), and no correlations were found between the rs7124442 polymorphism and the ischemic stroke subtypes (*P* \> 0.05). However, after logistic regression analysis was performed for the rs6265 locus with the correction of potential confounding factors (sex, age, smoking, drinking, hypertension, diabetes, hyperlipidemia and atrial fibrillation), a negative correlation was found between the AA genotype (recessive model) and the occurrence of ischemic stroke in patients with large-artery atherosclerosis (odds ratio, *OR* = 0.58; 95% confidence interval, 95% *CI*: 0.37--0.90; *P* = 0.015). Polymorphisms at the rs6265 locus were found not to correlate with the risk of ischemic stroke or the incidence of cardioembolism or small-artery occlusion (*P* \> 0.05).

###### 

Genotypes and allele frequencies between ischemic stroke cases and controls

  SNP            Allele/genotype   Ischemic stroke   Control     Chi^2^/STAT        *OR* (95% *CI*)   *P*
  -------------- ----------------- ----------------- ----------- ------------------ ----------------- -----
  rs6265         A                 682(47.4)         709(44.8)   --                 --                --
  G              758(52.6)         873(55.2)         1.96        1.11(0.96--1.28)   ^a^0.162          
  AA             153(21.2)         172(21.7)         --          --                 --                
  AG             376(52.2)         365(46.1)         --          --                 --                
  GG             191(26.5)         254(32.1)         --          --                 --                
  Dominant^b^    --                --                0.73        1.11(0.83--1.48)   0.467             
  Model                                                                                               
  AA+GA                                                                                               
  GG                                                                                                  
  Recessive^b^   --                --                --1.735     0.75(0.55--1.04)   0.083             
  Model                                                                                               
  AA                                                                                                  
  GA+GG                                                                                               
  rs7124442      C                 126(8.7)          133(8.6)    --                 --                --
  T              1326(91.3)        1415(91.4)        0.01        1.01(0.78--1.31)   0.924             
  CC             3(0.4)            6(0.8)            --          --                 --                
  TC             120(16.5)         121(15.6)         --          --                 --                
  TT             603(83.1)         647(83.6)         --          --                 --                
  Dominant       --                --                --0.14      0.98(0.69--1.39)   0.89              
  Model                                                                                               
  CC+TC                                                                                               
  TT                                                                                                  
  Recessive      --                --                --0.33      0.75(0.14--3.94)   0.739             
  Model                                                                                               
  CC                                                                                                  
  TC+TT                                                                                               

SNP: Single-nucleotide polymorphism; STAT: logistic coefficient *t* statistic; *CI*: confidence interval; *OR*: odds ratio. ^a^Chi-square test; ^b^logistic regression analyses adjusted on the basis of risk factors such as age, sex, hypertension, hyperlipidemia, diabetes, atrial fibrillation, smoking and drinking.

###### 

Genotypes and allele frequencies between TOAST subtype and controls

  SNP         Allele/genotype   Control \[*n*(%)\]   LAA (*n* = 281)   Cardioembolism (*n* = 160)   SAO (*n* = 210)                                                                                                                       
  ----------- ----------------- -------------------- ----------------- ---------------------------- ------------------- ---------- ----------- ----------- ------------------ ------- ----------- ----------- ------------------- ------- --
  rs6265      A                 709(44.8)            243(45.8)                                                                                 149(51.0)                                          175(46.1)                               
  G           873(55.2)         287(54.2)            Allelic^a^        0.17                         1.04 (0.86--1.27)   0.679      143(49)     3.83        1.28(1.00--1.65)   0.05    205(53.9)   0.19        1.05(0.84--1.32)    0.664   
  AA          172(21.7)         53(20)               --                --                           --                  --         31(21.2)    --          --                 --      43(22.6)    --          --                  --      
  AG          365(46.1)         137(51.7)            Dominant^b^       0.12                         1.02(0.70--1.50)    0.908      87(59.6)    1.64        2.06(0.87--4.90)   0.102   89(46.8)    --0.08      0.98(0.63--1.53)    0.937   
  GG          254(32.1)         75(28.3)             Recessive^b^      --2.44                       0.58(0.37--0.90)    0.015^c^   28(19.2)    --0.43      0.83(0.35--1.97)   0.666   58(30.5)    --0.21      0.95(0.59--1.53)    0.833   
  rs7124442   C                 133(8.6)             47(8.9)                                                                                   22(7.5)                                            35(8.8)                                 
  T           1415(91.4)        479(91.1)            Allelica          0.06                         1.04(0.74--1.48)    0.808      270(92.5)   0.36        0.87(0.54--1.39)   0.551   363(91.2)   0.02        1.03(0.69--1.52)    0.898   
  CC          6(0.8)            0                    --                --                           --                  --         0           --          --                 --      3(1.5)      --          --                  --      
  TC          121(15.6)         47(17.9)             Dominant^b^       0.34                         1.08(0.69--1.71)    0.732      22(15.1)    --0.4       0.82(0.3--2.22)    0.691   29(14.6)    --0.37      0.9(0.53--1.55)     0.713   
  TT          647(83.6)         216(82.1)            Recessive^b^      NA                           NA                  NA         124(84.9)   NA          NA                 NA      167(83.9)   1.26        3.13(0.53--18.55)   0.209   

SNP: Single-nucleotide polymorphism; LAA: large-artery atherosclerosis; SAO: small artery occlusion; STAT: logistic coefficient *t* statistic. ^a^Chi-square test; ^b^Logistic regression analyses adjusted on the basis of risk factors such as age, sex, hypertension, hyperlipidemia, diabetes, atrial fibrillation, smoking, and drinking; ^c^indicates significant differences at *P* \< 0.05; ^d^Stroke TOAST subtype cases*vs*. control group. Data of control group are the same as in **[Table 3](#T1){ref-type="table"}**.

rs7124442 and rs6265 genotypes/allele frequencies distribution and association with stroke severity at admission {#sec2-8}
----------------------------------------------------------------------------------------------------------------

The allele and genotype distribution frequencies in the mild and severe stroke groups are shown in **[Table 5](#T5){ref-type="table"}**. No significant differences were found in allele frequencies at the rs7124442 and rs6265 loci in the intergroup comparison (*P* \> 0.05). Logistic regression analysis revealed that the dominant and recessive models of the rs7124442 and rs6265 loci had no correlation with the severity of the neurological deficits during the acute phase (*P* \> 0.05). Because the distribution frequency of the CC genotype at the rs7124442 locus was zero in the severe stroke group, recessive model analysis was not performed.

###### 

Genotype and allele frequency distributions and association with severity at admission

  SNP            Allele/genotype   Mild (NIHSS ≤ 6) (*n* = 477)   Severe (NIHSS ≥ 7) (*n* = 301)   Chi^2^/STAT        *OR* (95%*CI*)   *P*
  -------------- ----------------- ------------------------------ -------------------------------- ------------------ ---------------- -----
  rs6265         A                 419(47.3)                      263(47.5)                        --                 --               --
  G              467(52.7)         291(52.5)                      0.005                            1.01(0.81--1.25)   0.946^a^         
  AA             98(22.1)          55(19.9)                       --                               --                 --               
  AG             223(50.3)         153(55.2)                      --                               --                 --               
  GG             122(27.5)         69(24.9)                       --                               --                 --               
  Dominant^b^    --                --                             0.45                             1.08(0.76--1.54)   0.652            
  Model                                                                                                                                
  AA+GA                                                                                                                                
  GG                                                                                                                                   
  Recessive^b^   --                --                             --0.79                           0.86(0.59--1.25)   0.431            
  Model                                                                                                                                
  AA                                                                                                                                   
  GA+GG                                                                                                                                
  rs7124442      C                 77(8.6)                        49(8.8)                          --                 --               --
  T              819(91.4)         507(91.2)                      0.02                             1.03(0.71--1.50)   0.885            
  CC             3(0.7)            0(0.00)                        --                               --                 --               
  TC             71(15.8)          49(17.6)                       --                               --                 --               
  TT             374(83.5)         229(82.4)                      --                               --                 --               
  Dominant       --                --                             0.43                             1.09(0.73--1.64)   0.665            
  Model                                                                                                                                
  CC+TC                                                                                                                                
  TT                                                                                                                                   
  Recessive      --                --                             NA                               NA                 NA               
  Model                                                                                                                                
  CC                                                                                                                                   
  TC+TT                                                                                                                                

SNP: Single-nucleotide polymorphism; NIHSS: National Institutes of Health Stroke Scale; STAT: logistic coefficient *t* statistic;*CI*: confidence interval; *OR*: odds ratio. ^a^Chi-square test; ^b^logistic regression analyses adjusted on the basis of risk factors such as age, sex, hypertension, hyperlipidemia, diabetes, atrial fibrillation, smoking and drinking.

rs7124442 and rs6265 genotypes, allele frequency distributions and association with stroke acute functional outcome {#sec2-9}
-------------------------------------------------------------------------------------------------------------------

The allele and genotype distribution frequencies in the good prognosis group (mRS score ≤ 1) and the poor prognosis group (mRS score ≥ 2) during the acute phase are shown in **[Table 6](#T6){ref-type="table"}**. In the intergroup comparison between the patients with good prognosis and those with poor prognosis, the risk of poor prognosis was lower in patients who carried a C allele at the rs7124442 locus than in T allele carriers (*OR* = 0.67; 95% *CI*: 0.45--1.00; *P* = 0.048). After logistic regression analysis was performed to correct for potential confounding factors (sex, age, smoking, drinking, hypertension, diabetes, hyperlipidemia and atrial fibrillation), the risk was lower in patients with the CC or TC genotype than TT carriers (*OR* = 0.65; 95% *CI*: 0.42--1.00; *P* = 0.049).

###### 

Genotype and allele frequency distributions and association with acute functional outcome

  SNP            Allele/genotype   Good (mRS ≤ 1) (*n* = 189)   Poor (mRS ≥ 7) (*n* = 589)   Chi^2^/STAT        *OR* (95% *CI*)   *P*
  -------------- ----------------- ---------------------------- ---------------------------- ------------------ ----------------- -----
  rs6265         A                 158(44.9)                    524(48.2)                    --                 --                --
  G              194(55.1)         564(51.8)                    1.14                         1.14(0.90--1.45)   0.285^a^          
  AA             35(19.9)          118(21.7)                    --                           --                 --                
  AG             88(50.0)          288(52.9)                    --                           --                 --                
  GG             53(30.1)          138(25.4)                    --                           --                 --                
  Dominant^b^    --                --                           1.26                         1.28(0.87--1.88)   0.209             
  Model                                                                                                                           
  AA+GA                                                                                                                           
  GG                                                                                                                              
  Recessive^b^   --                --                           0.64                         1.15(0.75--1.76)   0.525             
  Model                                                                                                                           
  AA                                                                                                                              
  GA+GG                                                                                                                           
  rs7124442      C                 40(11.2)                     86(7.8)                      --                 --                --
  T              316(88.8)         1010(92.2)                   3.9                          0.67(0.45--1.00)   0.048^c^          
  CC             1(00.6)           2(0.4)                       --                           --                 --                
  TC             38(21.3)          82(15.0)                     --                           --                 --                
  TT             139(78.1)         464(84.7)                    --                           --                 --                
  Dominant       --                --                           --1.97                       0.65(0.42--1.00)   0.049^c^          
  CC+TC                                                                                                                           
  TT                                                                                                                              
  Recessive      --                --                           --0.32                       0.67(0.06--7.68)   0.746             
  CC                                                                                                                              
  TC+TT                                                                                                                           

SNP: Single-nucleotide polymorphism; mRS: Modified Rankin Scale; STAT: logistic coefficient *t* statistic; *CI*: confidence interval; *OR*: odds ratio. ^a^Chi-square test; ^b^logistic regression analyses adjusted on the basis of risk factors such as age, sex, hypertension, hyperlipidemia, diabetes, atrial fibrillation, smoking and drinking; ^c^Indicates significant differences at *P* \< 0.05.

The allele frequency of rs6265 was not significantly different between the two groups (*P* \> 0.05), and the dominant and recessive models exhibited no correlation with prognosis (*P* \> 0.05).

Discussion {#sec1-4}
==========

In this study, for the first time, we studied the correlations between polymorphism at the *BDNF* rs7124442 (C/T) locus and acute ischemic stroke. We discovered that patients carrying a C allele at the rs7124442 locus showed a lower risk for poor prognosis than T allele carriers (*OR* = 0.67; 95% *CI*: 0.45--1.00; *P* = 0.048). Additionally, the risk of poor prognosis in carriers of the CC or TC genotype (dominant model) was significantly lower than that in the carriers of the TT genotype (*OR* = 0.65; 95% *CI*: 0.42--1.00; *P* = 0.049). We also found a correlation between the AA genotype (recessive model) at the rs6265 locus of the *BDNF* gene and the incidence of ischemic stroke in patiants with large-artery atherosclerosis (*OR* = 0.58; 95% *CI*: 0.37--0.90; *P* = 0.015).

The rs7124442 (C/T) locus is in the long 3′UTR of the *BDNF* gene. This untranslated sequence is immediately adjacent to the coding sequence in the mRNA and plays important roles in the post-transcriptional regulation of genes, such as involvement in mRNA transport and translation efficiency (Mignone et al., 2002). A study has shown that variations of polymorphisms at the rs7124442 (C/T) locus are associated with cognitive recovery after traumatic brain injury (Rostami et al., 2011), but there are still relatively few studies on this topic. No studies have reported on the correlation between polymorphisms at this locus with ischemic stroke susceptibility, neurological deficits during the acute phase and prognosis.

We are the first to study the correlation between polymorphism at the rs7124442 locus and acute ischemic stroke. The 3′UTR plays important regulatory roles in the transcription and translation of genes. Two studies found no significant associations between the rs7124442 (C/T) locus and *BDNF* levels (Hohenadel et al., 2014; Failla et al., 2016). However, one study found that rs7124442 in the long 3′UTR inhibited dendritic localization of *BDNF* mRNA (Orefice et al., 2013). Further mechanistic studies are needed to clarify how rs7124442 (C/T) locus polymorphism can influence the prognosis of stroke. No correlation was found between rs7124442 and ischemic stroke susceptibility and the severity of neurological deficits during the acute phase.

In this study, only the AA genotype (recessive model) at the rs6265 locus of the *BDNF* gene was negatively correlated with the occurrence of ischemic stroke in patients with large-artery atherosclerosis (*OR* = 0.58; 95% *CI*: 0.37--0.90; *P* = 0.015). This finding is not consistent with the results of previous studies. Zhao et al. (2013) found a correlation between the AA genotype of the rs6265 locus and the incidence of ischemic stroke, but no such correlation in subtype analyses. Additionally, in an Iranian population, Keshavarz et al. (2016) found that the GA or GG genotypes at the rs6265 locus are associated with the incidence of ischemic stroke. This discrepancy is likely due to different the populations included in these studies. This study only included the Han population in southwest China, while the population studied by Zhao et al. (2013) was mainly from the Shanghai area.

Other research has shown that BDNF may be associated with neurological deficits in the central nervous system. For example, Qin et al. (2011) found that knock-in mice with a *BDNF* mutation (Met/Met) had reduced *BDNF* levels in the central nervous system when compared with wild-type mice (Val/Val); this reduction was associated with motor function impairment severity. However, no correlations were found between the rs6265 polymorphism and the severity of neurological deficits during the acute phase of ischemic stroke in our study. In fact, this finding is consistent with the results from previous clinical studies in China and other countries (Zhao et al., 2013; Stanne et al., 2014). However, this finding is not consistent with the results of animal studies by Qin et al. (2011), though the reasons for this inconsistency require further investigation. One possible reason is that the factors affecting the severity of neurological deficits in the human body are more diverse than those in an animal ischemic stroke model and that the interactions between these factors are more complex.

When ischemic stroke prognosis was assessed using mRS scores, the current findings on the rs6265 polymorphism and prognosis were not consistent. In this study, the rs6265 polymorphism was not found to be associated with early ischemic stroke prognosis. Furthermore, no correlations were found between the rs6265 polymorphism and the prognosis of ischemic stroke patients in populations from Europe and the US (Cramer et al., 2012; Stanne et al., 2014). However, a study in the Korean population showed that the rs6265 polymorphism was not associated with prognosis at 30 days after ischemic stroke, but was associated with prognosis at 90 days after ischemic stroke (Kim et al., 2013). In another study of the Korean population, rs6265 polymorphism was found to be associated with poor prognosis at 14 days and 1 year after ischemic stroke (Kim et al., 2012). In the Chinese population, Zhao et al. (2013) found that the AA genotype was associated with poor prognosis at 90 days after ischemic stroke. The differences in these findings suggest that the rs6265 polymorphism exhibits differences in different races. Therefore, our results require further confirmation in different races with large samples.

There are some limitations in this study.First, this study is a single-center study with a small sample size. The patients showed significant differences in age and sex when compared with the control group. Our results need further confirmation through multi-center studies of larger sample sizes matched in sex and age, because ischemic stroke is a complex disease that has a high incidence and is influenced by multiple gene interactions, the environment, and lifestyle. Second, this study only included the Han population in southwestern China, and its findings need to be further verified in different ethnic populations in different regions. Third, only two hotspot single-nucleotide polymorphisms of the *BDNF* gene were selected in this study, and the correlations between ischemic stroke and other *BDNF* single-nucleotide polymorphisms should be elucidated in subsequent studies to further clarify the relationship between the *BDNF* gene and ischemic stroke. Finally, this study included patients with ischemic stroke within 7 days of onset; the NIHSS score was assessed on the day of admission to assess the severity of neurological deficits, and the mRS score was evaluated on the day of discharge for early prognosis. Therefore, the two assessments of the patients may not be on the same timeline. Additionally, the observation period for ischemic stroke prognosis was short. The correlations between *BDNF* gene polymorphisms and long-term ischemic stroke prognosis should be further observed in follow-up studies.

For the first time, we discovered that the C allele (CC or TC genotypes) at the rs7124442 locus is likely a protective factor for ischemic stroke prognosis. We also found that the AA genotype of rs6265 is possibly a protective factor for the occurrence of ischemic stroke in patients with large-artery atherosclerosis. The mechanisms underlying the above observations should be further verified in subsequent studies.
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  Study design                                                                                                                                                                                                                                                                              4        Present key elements of study design early in the paper                                                                                                                                                                                                                                                                                                                                                                                               3
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  Participants                                                                                                                                                                                                                                                                              6        (a)*Cohort study*---Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up *Case-control study*---Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls *Cross-sectional study*---Give the eligibility criteria, and the sources and methods of selection of participants   3
  *(b) Cohort study*---For matched studies, give matching criteria and number of exposed and unexposed *Case-control study*---For matched studies, give matching criteria and the number of controls per case                                                                               3                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Variables                                                                                                                                                                                                                                                                                 7        Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable                                                                                                                                                                                                                                                                                                              5
  Data sources/ measurement                                                                                                                                                                                                                                                                 8\*      For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group                                                                                                                                                                                                                                                                  5
  Bias                                                                                                                                                                                                                                                                                      9        Describe any efforts to address potential sources of bias                                                                                                                                                                                                                                                                                                                                                                                             3,5
  Study size                                                                                                                                                                                                                                                                                10       Explain how the study size was arrived at                                                                                                                                                                                                                                                                                                                                                                                                             n/a
  Quantitative variables                                                                                                                                                                                                                                                                    11       Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why                                                                                                                                                                                                                                                                                                                          5
  Statistical methods                                                                                                                                                                                                                                                                       12       *(a)* Describe all statistical methods, including those used to control for confounding                                                                                                                                                                                                                                                                                                                                                               5,6
  *(b)* Describe any methods used to examine subgroups and interactions                                                                                                                                                                                                                     n/a                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  *(c)* Explain how missing data were addressed                                                                                                                                                                                                                                             n/a                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  *(d) Cohort study*---If applicable, explain how loss to follow-up was addressed *Case-control study*---If applicable, explain how matching of cases and controls was addressed *Cross-sectional study*---If applicable, describe analytical methods taking account of sampling strategy   n/a                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                     \(e\) Describe any sensitivity analyses                                                                                                                                                                                                                                                                                                                                                                                                               5
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  Participants                                                                                                                                                                                                                                                                              13\*     \(a\) Report numbers of individuals at each stage of study---eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed                                                                                                                                                                                                                                                 4,6
  \(b\) Give reasons for non-participation at each stage                                                                                                                                                                                                                                    4                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  \(c\) Consider use of a flow diagram                                                                                                                                                                                                                                                      4                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Descriptive data                                                                                                                                                                                                                                                                          14\*     \(a\) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders                                                                                                                                                                                                                                                                                                            6,7
  \(b\) Indicate number of participants with missing data for each variable of interest                                                                                                                                                                                                     n/a                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  (c)*Cohort study*---Summarise follow-up time (eg, average and total amount)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Outcome data                                                                                                                                                                                                                                                                              15\*     *Cohort study*---Report numbers of outcome events or summary measures over time                                                                                                                                                                                                                                                                                                                                                                       
  *Case-control study*---Report numbers in each exposure category, or summary measures of exposure                                                                                                                                                                                          6-12                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  *Cross-sectional study*---Report numbers of outcome events or summary measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Main results                                                                                                                                                                                                                                                                              16       *(a)* Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included                                                                                                                                                                                                                                        6-12
  (*b*) Report category boundaries when continuous variables were categorized 6-12                                                                                                                                                                                                          n/a                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period n/3                                                                                                                                                                    n/a                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Other analyses                                                                                                                                                                                                                                                                            17       Report other analyses done---eg analyses of subgroups and interactions, and sensitivity analyses                                                                                                                                                                                                                                                                                                                                                      
  **Discussion**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Key results                                                                                                                                                                                                                                                                               18       Summarise key results with reference to study objectives                                                                                                                                                                                                                                                                                                                                                                                              15
  Limitations                                                                                                                                                                                                                                                                               19       Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias                                                                                                                                                                                                                                                                                            13,14,15
  Interpretation                                                                                                                                                                                                                                                                            20       Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence                                                                                                                                                                                                                                                                            
  Generalisability                                                                                                                                                                                                                                                                          21       Discuss the generalisability (external validity) of the study results n/3                                                                                                                                                                                                                                                                                                                                                                             n/a
  **Other information**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Funding                                                                                                                                                                                                                                                                                   2222     Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based                                                                                                                                                                                                                                                                                         1,16

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
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